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ABSTRACT Total chemical synthesis of analog proteins
was used to examine the requirement for specific disulfide
bridges for the biological activity of interleukin 3 (IL-3), a
growth factor that stimulates multiple lineages of hemopoietic
cells. Four structural analogs of the mature, 140 amino acid
murine IL-3 molecule were synthesized in which specific
cysteine residues were replaced by alanines. In a quantitative
IL-3 assay, based on [3H~thymidine incorporation into factor-
dependent cells, the IL-3 analog with alanines substituted for
all four cysteines-i.e., [Alal7,7980, 4l41IL-3-had 1/500th as
much activity as the molecule synthesized according to the
native sequence. The two analogs [Cys17,79,Ala"0 "4nIL-3 and[Cys17,140,Ala79 8]IL-3 had similarly low activity, whereas the
[Cysl780A.la79,141IL-3 analog had 2000-fold higher activity
than these three analogs, and 3-fold higher than the molecule
with the native sequence. This shows that in IL-3 a single
disuflide bridge, between cysteines 17 and 80, is required for
biological activity that approximates physiological levels. This
disulfide probably stabilizes the tertiary structure of the
protein to give a conformation that is optimal for function.
The growth and differentiation of cells of the hemopoietic
lineage are regulated by several glycoprotein growth factors
(1). One of these, which has been best characterized in the
mouse, is now widely termed interleukin 3 (IL-3) but has also
been termed P-cell-stimulating factor, mast cell growth fac-
tor, burst-promoting activity, and multi-colony-stimulating
factor (2-7). IL-3 stimulates multiple hemopoietic cell types,
including pluripotential stem cells, committed progenitors,
and some mature cells (1, 7, 8). Murine IL-3 has been purified
to homogeneity (4, 9), and cDNA and genomic DNA clones
that encode the protein have been isolated (10-12). The
protein sequence deduced from the DNA sequences (10, 11)
and N-terminal amino acid sequence analysis (9, 13) indicated
that mature IL-3 contains 140 amino acid residues. However,
a shorter form, lacking the first 6 amino acids, has also been
identified (4). Recent experiments with antibodies to syn-
thetic peptide fragments indicate that the IL-3 produced by
activated T cells is the full-length, 140-residue form (14).
Neither the location of disulfide bridges (if any) nor the
three-dimensional structure of the molecule is known.
We have investigated the structural basis for IL-3 function
by a total chemical synthesis approach (15). The ability to
reproducibly synthesize IL-3 with high activity has allowed
us to systematically vary its structure and compare the
biological activities of the analogs with those of the molecule
with the native sequence. In our previous study we demon-
strated that the cysteine at position 17 was essential for
detectable activity. A fragment corresponding to residues 18-
140, and therefore lacking this cysteine, had barely detectable
activity, whereas a fragment (residues 17-140) that included
the cysteine at position 17 had high activity. The most likely
explanation of this result was that Cys-17 is involved in a
critical disulfide bridge, suggesting a role for disulfides in
forming or maintaining the active structure (15).
Here we further analyze the role of disulfide bridges in
determining the biological activity of IL-3. By constructing
an analog with alanines substituted for all four cysteines, we
have found that cysteines are not absolutely required for
activity. However, an analog with a disulfide bridge between
residues 17 and 80 (but not analogs with alternative disulfide
bridges) had 2000-fold greater activity, suggesting that this
disulfide bond stabilized a functionally favorable conforma-
tion of the molecule.
MATERIALS AND METHODS
Chemical Synthesis. IL-3 and IL-3 analogs (Fig. 1) were
synthesized by improved chemical methods (16-18) on a fully
automated peptide synthesizer (model 430A, Applied Bio-
systems, Foster City, CA) (19) as described (15, 17, 18). Fully
protected peptide-resins were stored in dimethylformamide
in liquid nitrogen, and aliquots (750 mg) were deprotected as
follows. The imidazole dinitrophenyl groups were removed
from histidine residues by treatment with 2-mercaptoethanol
(20%) and diisopropylethylamine (5%) in dimethylforma-
mide; then the Na-t-butoxycarbonyl group was removed by
treatment with trifluoroacetic acid (65%) in dichloromethane
(18); all remaining protecting groups were removed and the
peptide was released from the resin by treatment with
anhydrous hydrogen fluoride according to the "low-high"
procedure (21). Peptides were precipitated and extracted
with ethyl acetate, dissolved in 5% acetic acid, lyophilized,
and stored at - 20'C. Aliquots (100 mg) of the crude lyophi-
lized product were dissolved in 6 M guanidine hydrochlo-
ride/0.1 M Tris acetate, pH 8.5/20% 2-mercaptoethanol (4
ml) and stirred for 2 hr at 370C. The synthetic product was
exchanged into 0.1 M acetic acid on Sephadex G-25 and
added to 1000 ml of 1 M guanidine hydrochloride/Tris
acetate, pH 8.5, and stirred vigorously for 16 hr at room
temperature in an open beaker. After addition of 10 ml of
acetic acid, the mixture was concentrated by filtration (Am-
icon YM5 membrane) in a stirred cell (Amicon), dialyzed
against 0.1 M acetic acid, and then filtered through a 0.2-pm
filter (Nalgene) and lyophilized. For bioassay a sample was
dissolved in 0.1 M acetic acid (1 mg/ml) and the concentra-
tion of peptide was established by quantitative amino acid
analysis.
Sulihydryl Assay. Aliquots (200 gg) were analyzed for free
thiol groups by the Ellman method (22). Dithiothreitol was
used as a standard.
Abbreviation: IL-3, interleukin 3.
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FIG. 1. Sequences ofthe murine IL-3 analogs synthesized and ofhuman IL-3. The sequence of murine IL-3 (A) was determined by translation
ofthe nucleotide sequences of IL-3 cDNAs and by amino acid sequence analysis of the purified native protein (9-11, 13). The analogs synthesized
'were [Alal7,79,80,l1IL-3 (B), [Cys17"140,Alaw'9 IL-3 (C), [Cys17',Ala80-41IL-3 (D), and [Cys17'80,Ala79'141IL-3 (E). The human IL-3 sequence (F)
was deduced by translation ofa human IL-3 cDNA clone (20). Alignment ofA and Fwas done as described (20). Amino acids are numbered according
to the mouse IL-3 sequence without counting spaces necessary for alignment with the human sequence. Standard one-letter amino acid symbols are
shown.
Tryptic Peptide Mapping. Tryptic digests were prepared
and chromatographed by reverse-phase high-performance
liquid chromatography (HPLC) on a C18 column (Altex) as
described (15). Amino acid analysis was carried out on
samples hydrolyzed in 6 M HCl vapor at 110°C for 6 hr and
derivatized with dimethylaminoazobenzenesulfonyl chloride
and analyzed as described (23). Peptide sequencing was
carried out on a gas-phase sequenator (24) and the phenyl-
thiohydantoins of the amino acids were analyzed by reverse-
phase HPLC (25).
NaDodSO4/PAGE. NaDodSO4/PAGE was carried out in
12.5-20% acrylamide gels with the Laemmli buffer system
(26). Standards (Bio-Rad) were phoshorylase b (94 kDa),
bovine serum albumin (67 kDa), ovalbumin (43 kDa), car-
bonic anhydrase (30 kDa), soybean trypsin inhibitor (21 kDa),
and a-lactalbumin (14 kDa).
Reverse-Phase HPLC. All the analogs were partially puri-
fied by reverse-phase HPLC on a Vydac C4 column (4.6 x
250 mm) by elution with a 0-60% acetonitrile gradient in 0.1%
trifluoroacetic acid at 1 ml/min. Fractions (0.5 ml) were
tested for IL-3 activity, and for purity by isoelectric focusing.
In each case, fractions containing the highest activity gave a
predominant band with an approximate pI of 8.5.
IL-3 Assays. IL-3 assays were performed by measuring the
[3H]thymidine incorporation of the IL-3-dependent mast cell
line W/W.12 as described (9).
RESULTS AND DISCUSSION
Design of Analogs. Our strategy for establishing the role of
disulfide bridges in determining the biological activity of IL-3
was to chemically synthesize defined structural analogs ofthe
protein in which nonsulfhydryl-containing amino acids were
substituted for cysteines and to correlate the structural
changes with effects on biological activity. Two naturally
occurring amino acids, serine and alanine, might be consid-
ered suitable replacements for cysteine. We chose alanine as
the replacement amino acid because this represents a mini-
mum structural change with deletion of only the sulfhydryl
functionality. IL-3 contains four cysteines, at positions 17,
79, 80, and 140 (Fig. 1). We designed analogs in which
alanines were substituted for one pair of cysteine residues,
thus generating molecules with only two cysteine residues.
With these analogs only two possible monomeric forms can
exist: a polypeptide with a single disulfide bridge or a form
with no disulfide bridges. An analog with alanines substituted
for all four naturally occurring cysteines was used as a basis
for comparison of the effects of forming the various combi-
nations of single disulfides.
Synthesis and Characterization. The analogs were synthe-
sized as complete 140-residue polypeptide chains by stepwise
solid-phase peptide synthesis methods (27). Some analogs,
for example [Cys'7,140 Ala79'8`]IL-3, were made by a diver-
gent synthesis protocol in which about two-thirds of the
peptide-resin was taken after the addition of residue 81 and
stored for future assembly of analogs that share the C-
terminal 60 amino acid residues. Storage in dimethylforma-
mide in liquid nitrogen or at - 80°C was found to prevent the
artifactual termination of chain growth that we observed
when dried peptide-resins were stored at 4°C.
The synthesizer was programmed to automatically take
samples after each cycle of the chain assembly, up to the
addition of residue 81 (59 cycles), for analysis of unreacted
a-amino groups by the quantitative ninhydrin procedure (28).
For both the [Cys140]IL-3-(81-140) and [Ala"]IL-3-(81-140)
analogs the results showed reproducible average stepwise
yields of 99.5% per residue. Samples were not taken for
cycles after residue 81 because the progressive reduction in
the concentration of growing peptide chains (mmol/g of
peptide-resin), and the rise in background, made the results
less reliable. When each 140-residue protected-peptide chain
had been assembled, samples were deprotected and cleaved
from the solid support by using the improved "low-high"
hydrogen fluoride strategy (21) and further characterized. All
the analog syntheses were performed at least twice with
similar results.
The synthetic polypeptides were each run on NaDod-
S04/PAGE under nonreducing and reducing conditions. As
shown in Fig. 2 the reduced synthetic products each had an
apparent molecular mass of 16 kDa, which was consistent
with the theoretical molecular weights of between 15,636 and
15,734. Under nonreducing conditions none of the unpuri-
fied, folded peptide products contained high molecular
weight material, showing that polymerization had not oc-
curred during the synthesis or folding process. After the
disulfide bridges were formed by mild oxidation, each syn-
thetic IL-3 analog was analyzed for free sulfhydryl content by
using the Ellman reagent (22). None of the folded, oxidized
analogs had detectable (<0.05 mol/mol of protein) free
sulfhydryl groups, although after reduction and removal of
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FIG. 2. NaDodSO4/PAGE analysis of IL-3 analogs. Lanes: A,
molecular size standards; B, [Alal7 '7980l140]IL-3; C, [Cys'17140,
Ala79801IL-3; D, [Cys7 79Ala80 140]IL-3; E, [Cys ' 0Ala' 0] ;
F, [Cys17'79'80,"'IL-3. Standards and electrophoresis conditions are
detailed in Materials and Methods.
the free reducing agent, the IL-3 analogs containing cysteines
had readily detectable sulfhydryl groups in the expected
amounts. The [Ala17'79'801 ]IL-3 analog did not give a
positive reaction with the Ellman reagent under these con-
ditions. These results, combined with the NaDodSO4/PAGE
data showing lack of intermolecular crosslinking, demon-
strated that the appropriate intramolecular disulfide bridges
were quantitatively formed.
The primary structures of the IL-3 analogs were compared
by analyzing their tryptic peptide maps (Fig. 3). The reduced
tryptic peptide HPLC profiles were similar, as would be
expected for polypeptides with closely related primary struc-
tures. Previous peptide mapping of synthetic IL-3 (15) al-
lowed the identification of tryptic fragments containing resi-
dues 17, 79, 80, and 140. For each analog, the tryptic peptides
containing either residue 17 or 140 were collected and sub-
jected to amino acid analysis to confirm the cysteine/alanine
content. In the case of tryptic peptides covering residues 77-
96 (peaks 3 in Fig. 3) and thus containing residues 79 and 80,
amino acid sequence analysis was carried out. The results
confirmed that the synthetic analogs had alanines located in
the expected peptide fragments or, in the case of peptide 77-
96, in the expected positions. Taken together these results
confirmed that the synthetic products had the expected phy-
siochemical and structural properties.
Activity of Synthetic Analogs. Before analysis for biological
activity, each IL-3 analog was purified by reverse-phase
HPLC. The purified analogs were analyzed for their ability to
stimulate [3H]thymidine incorporation in an IL-3-dependent
cell line. As shown in Fig. 4 the [Cys1780,Ala79140]IL-3
analog had the greatest activity in the IL-3 assay. A 50%
maximal response occurred at a concentration (EC50) of 4.3
x 10-11 M. Thus, this analog was about 2000 times more
active than the [Ala"7 79,80,140]IL-3 analog (EC50 = 7.9 x
10-8 M). Moreover, the two analogs with alanines substi-
tuted at alternative positions-i.e., [Cys17,79,Ala8O"'40]IL-3
and [Cys17,140,Ala79,80]IL-3-had activities (EC509.8 x 10-8
M and 6.3 x 10-8 M, respectively) that were similar to that
of the analog with all four cysteines converted to alanines-
i.e., [Ala17'79'80,140]IL-3. In the same assay, purified, Esch-
erichia coli-derived recombinant IL-3 (a gift of Biogen
Research, Cambridge, MA) was about 3-fold more active
(EC50 = 1.4 x 10-11 M) than [Cys17 '80,Ala79"140IL-3. The
difference could be due to residual impurities in the HPLC-
purified synthetic product, since isoelectric focusing exper-
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FIG. 3. Tryptic peptide maps of the IL-3 analogs. Tryptic digests
of the folded unpurified IL-3 analogs were reduced with 0.1 M
dithiothreitol and subjected to reverse-phase HPLC. (A)
[Ala" 79'80,40]IL-3. (B) [Cys17"140,Ala79'80]IL-3. (C) [Cys17'9,-
Ala"0"1401IL-3. (D) [Cys 7'8,Ala 9"l1IL-3. Peaks containing cy-
steines or alanine replacements, labeled 1, 2, and 3, were identified
by comparison with peptide maps of synthetic IL-3 (15) and the
compositions determined by amino acid analysis (peaks 1 and 2) and
peptide sequence analysis (peaks 3). Peaks are as follows: la,[Ala'n°IL-3-(136-140); lb, [Cysl4°1L-3-(l36-140); 2a, [Ala17]IL-3-
(14-22); 2b, [Cys'7]IL-3-(14-22); 3a, [Ala79'80]IL-3-(77-96); 3b,[Cys'9,AlaN1JL-3-(77-96); and 3c, [Ala79,Cys°]IL-3-(77-96).
iments indicated that, in addition to the major band that was
apparent, minor silver-staining bands were also present.
Activity of the IL-3 analog without cysteines was some-
what surprising in view of our previous experiments showing
that a fragment that lacked Cys-17 did not have activity (15).
It is possible that this IL-3-(18-140) fragment, which contains
three cysteines, forms disulfide bridges between cysteines 79
and 140 or 80 and 140 and that this prevents the active tertiary
structure from being generated. Nevertheless, the more than
2000-fold greater activity of the [Cys17'80,Ala79 140]IL-3 ana-
log supports our contention (15) that a disulfide involving
Cys-17 is required for full biological activity. The data further
suggest that Cys-17 and Cys-80 are paired in a disulfide bridge
in native murine IL-3.
The analog with the "correct" cysteines paired (17 and 80)
was actually 3-fold more active than the synthetic molecule
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FIG. 4. Biological activity of HPLC-purified synthetic IL-3 analogs. Shown are titrations of [Cys'7'79,Ala8O"14"1IL-3 (m), [Cys17,140,Ala79,80'-
IL-3 (o), [Cys17'80,Ala79"4O]IL-3 (9), [Ala7,79'80'140]IL-3 (A), and [Cys1'779'80'1,1IL-3 (A). Protein concentrations were established by measuring
the absorbance at 214 nm (1 mg/ml = 15 absorbance units).
corresponding to the natural sequence (EC50 4.3 x 10-1 M
and 1.5 x 10-10 M, respectively). This probably reflects the
fact that the IL-3 molecule contains four cysteines and it
would be expected that some "incorrectly" folded mole-
cules, stabilized by mispaired disulfides, would form during
the folding/cysteine-oxidation process. These incorrectly
folded products were probably not completely resolved
during the HPLC purification and from the data presented
(Fig. 4) would be predicted to have substantially lower
activity.
In our earlier study (15) we showed that the disulfide-
bridged form of the synthetic fragment IL-3-(1-79) had low
but detectable activity (EC50 = 3 x 10- 5 M). In view of the
high activity of the full-length analog in which Cys-17 is
paired with Cys-80, it seemed possible that a fragment
containing Cys-17 and Cys-80 might have greater activity.
However, this was not the case, in that both IL-3-(1-79) and
[Ala79]IL-3-(1-80) had similar EC50 values of about 3.3 x
10-5 M. The fact that Cys-79 is replaced by a proline in the
human sequence suggested that proline may be a more
optimal replacement in the human fragment. This was indeed
found to be the case, as [Pro79]IL-3-(1-80) had a significantly
lower EC50 (7.6 x 10-6 M) than [Ala79]IL-3-(1-80).
Conclusions. The results described here represent strong
evidence that Cys-17 and Cys-80 in murine IL-3 form a
disulfide bridge and are crucial for the biological activity of
this lymphokine, whereas Cys-79 and Cys-140 are not re-
quired for activity. However, the results do not rule out the
possible existence of a second disulfide, between the cys-
teines at positions 79 and 140, in native mouse IL-3. Inter-
estingly, there are only two cysteine residues present in the
human IL-3 molecule, and these coincided with cysteines 17
and 80 in the mouse IL-3 molecule when the two sequences
were computer-aligned (20). This suggests that during evo-
lution there was no selective pressure to retain the cysteines
at positions 79 and 140. That a disulfide bridge between
Cys-17 and Cys-79 does not yield a fully active murine
molecule and that Cys-79 is replaced by a proline in the
human molecule suggest the spatial orientation of the 17-80
disulfide is critical for correct folding. Our findings support
the contention that, despite the relatively weak homology
(29% amino acid identity), the gene for human IL-3 molecule
isolated by Yang et al. (20) is indeed a homolog of the murine
molecule, not only at the level of primary sequence but also
at the level of the three-dimensional structure as determined
by the disulfide bridge between residues 17 and 80.
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